Rigel Pharmaceuticals

RIGL64

$13.64arrow_drop_up0.07%$0.01

RIGL64

$13.64

arrow_drop_up0.07%$0.01

Performance History

Key Stats
Open	$13.59
Prev. Close	$13.68
EPS	-0.77
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$240.69M
PE Ratio	-

	LOW	HIGH
Day Range	13.37	14.11
52 Week Range	7.10	17.30

Ratios







EPS	-0.77

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Rigel Pharmaceuticals (RIGL)

Rigel Pharmaceuticals Inc (RIGL) is a biotechnology company that focuses on the discovery, development, and commercialization of novel small molecule drugs for the treatment of immune and hematologic disorders, cancer, and viral infections. The company's lead product candidate is fostamatinib, an oral spleen tyrosine kinase inhibitor that is in late-stage clinical development for the treatment of immune thrombocytopenic purpura (ITP) and autoimmune hemolytic anemia (AIHA). RIGL stock has a market cap of $600 million.

Rigel Pharmaceuticals Inc is well-positioned in the biopharmaceutical industry, with its innovative pipeline of drugs and a strong research and development team. The company's PEG ratio of 0.30 indicates that it is undervalued relative to its expected earnings growth. Rigel Pharmaceuticals Inc has outperformed the industry average in terms of stock price performance over the past year, with a 52-week range of $2.35 to $7.45. The stock is currently trading in the middle of this range at $4.40, reflecting a day range of $4.30 to $4.50. The trading volume for RIGL stock has been consistently strong, indicating investor interest in the company's potential.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Raul R. Rodriguez
Headquarters: South San Francisco
Employees: 155
Exchange: NASDAQ

Keep an eye on Rigel Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Rigel Pharmaceuticals 's (RIGL) price per share?

The current price per share for Rigel Pharmaceuticals (RIGL) is $13.64. The stock has seen a price change of $0.01 recently, indicating a 0.07% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Rigel Pharmaceuticals (RIGL)?

For Rigel Pharmaceuticals (RIGL), the 52-week high is $17.3, which is 26.83% from the current price. The 52-week low is $7.1, the current price is 92.11% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Rigel Pharmaceuticals (RIGL) a growth stock?

Rigel Pharmaceuticals (RIGL) has shown an average price growth of 0.41% over the past three years. It has received a score of 19 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Rigel Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Rigel Pharmaceuticals (RIGL) stock price performance year to date (YTD)?

As of the latest data, Rigel Pharmaceuticals (RIGL) has a year-to-date price change of -6.58%. Over the past month, the stock has experienced a price change of 7.32%. Over the last three months, the change has been 51.1%. Over the past six months, the figure is 1.79%. Looking at a longer horizon, the five-year price change stands at -19.76%.

help

Is Rigel Pharmaceuticals (RIGL) a profitable company?

Rigel Pharmaceuticals (RIGL) has a net income of -$25.09M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 93.92% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 1.21% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $116.88M, although specific revenue growth data is currently not available. The gross profit is $109.77M. Operating income is noted at -$20.49M. Furthermore, the EBITDA is -$7.52M.

help

What is the market capitalization of Rigel Pharmaceuticals (RIGL)?

Rigel Pharmaceuticals (RIGL) has a market capitalization of $239.82M. The average daily trading volume is 81.18K, indicating the stock's liquidity and investor engagement.